Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008 (2008), Article ID 245410, 12 pages
http://dx.doi.org/10.1155/2008/245410
Review Article

PPAR Agonists and Cardiovascular Disease in Diabetes

JDRF Center for Diabetes Complications, Baker Heart Research Institute, Melbourne, VIC 3004, Australia

Received 18 July 2007; Accepted 4 October 2007

Academic Editor: Brian N. Finck

Copyright © 2008 Anna C. Calkin and Merlin C. Thomas. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. B. Kannel and D. L. McGee, “Diabetes and cardiovascular disease: the Framingham study,” Journal of the American Medical Association, vol. 241, no. 19, pp. 2035–2038, 1979. View at PublisherView at Google Scholar
  2. J. Stamler, O. Vaccaro, and J. D. Neaton et al., “Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial,” Diabetes Care, vol. 16, no. 2, pp. 434–444, 1993. View at PublisherView at Google Scholar
  3. M. E. Cooper and C. I. Johnston, “Optimizing treatment of hypertension in patients with diabetes,” Journal of the American Medical Association, vol. 283, no. 24, pp. 3177–3179, 2000. View at PublisherView at Google Scholar
  4. M. C. Thomas and A. J. Weekes, Type 2 diabetes from the GP's perspective, Ph.D. thesis, Kidney Health Australia, Melbourne, Australia, 2007.
  5. A. P. Burke, F. D. Kolodgie, and A. Zieske et al., “Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 7, pp. 1266–1271, 2004. View at PublisherView at Google Scholar
  6. P. R. Moreno and V. Fuster, “New aspects in the pathogenesis of diabetic atherothrombosis,” Journal of the American College of Cardiology, vol. 44, no. 12, pp. 2293–2300, 2004. View at PublisherView at Google ScholarView at PubMed
  7. I. Inoue, S.-I. Goto, and K. Mizotani et al., “Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1β, interleukin-6, cyclooxygenase- 2, and p22phox by regulation of peroxisome proliferator-activated receptor α (PPAR α) in primary endothelial cells,” Life Sciences, vol. 67, no. 8, pp. 863–876, 2000. View at PublisherView at Google Scholar
  8. A. C. Calkin, M. E. Cooper, and K. A. Jandeleit-Dahm, “Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation,” Diabetologia, vol. 49, no. 4, pp. 766–774, 2006. View at PublisherView at Google ScholarView at PubMed
  9. A. C. Calkin, J. M. Forbes, and C. M. Smith et al., “Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 9, pp. 1903–1909, 2005. View at PublisherView at Google ScholarView at PubMed
  10. N. Marx, D. Walcher, and N. Ivanova et al., “Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products,” Diabetes, vol. 53, no. 10, pp. 2662–2668, 2004. View at PublisherView at Google Scholar
  11. N. Marx, J. Froehlich, and L. Siam et al., “Antidiabetic PPARγ-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 2, pp. 283–288, 2003. View at PublisherView at Google Scholar
  12. B. M. Spiegelman, “PPAR-γ: adipogenic regulator and thiazolidinedione receptor,” Diabetes, vol. 47, no. 4, pp. 507–514, 1998. View at PublisherView at Google Scholar
  13. M. Ricote, A. C. Li, and T. M. Willson et al., “The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998. View at PublisherView at Google ScholarView at PubMed
  14. C. Blanquart, O. Barbier, J. C. Fruchart, B. Staels, and C. Glineur, “Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation,” Journal of Steroid Biochemistry and Molecular Biology, vol. 85, no. 2–5, pp. 267–273, 2003. View at PublisherView at Google Scholar
  15. C. Blanquart, R. Mansouri, R. Paumelle, J.-C. Fruchart, B. Staels, and C. Glineur, “The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor α,” Molecular Endocrinology, vol. 18, no. 8, pp. 1906–1918, 2004. View at PublisherView at Google Scholar
  16. I. Inoue, K. Shino, S. Noji, T. Awata, and S. Katayama, “Expression of peroxisome proliferator-activated receptor α (PPAR α) in primary cultures of human vascular endothelial cells,” Biochemical and Biophysical Research Communications, vol. 246, no. 2, pp. 370–374, 1998. View at PublisherView at Google ScholarView at PubMed
  17. P. Delerive, F. Martin-Nizard, and G. Chinetti et al., “Peroxisome proliferator-activated receptor activators inhibit thrombin- induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway,” Circulation Research, vol. 85, no. 5, pp. 394–402, 1999.
  18. B. Staels, W. Koenig, and A. Habib et al., “Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators,” Nature, vol. 393, no. 6687, pp. 790–793, 1998. View at PublisherView at Google ScholarView at PubMed
  19. G. Chinetti, S. Griglio, and M. Antonucci et al., “Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages,” Journal of Biological Chemistry, vol. 273, no. 40, pp. 25573–25580, 1998. View at PublisherView at Google Scholar
  20. N. Vu-Dac, K. Schoonjans, B. Laine, J.-C. Fruchart, J. Auwerx, and B. Staels, “Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element,” Journal of Biological Chemistry, vol. 269, no. 49, pp. 31012–31018, 1994.
  21. N. Vu-Dac, K. Schoonjans, and V. Kosykh et al., “Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor,” Journal of Clinical Investigation, vol. 96, no. 2, pp. 741–750, 1995. View at PublisherView at Google Scholar
  22. G. Chinetti, F. G. Gbaguidi, and S. Griglio et al., “CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors,” Circulation, vol. 101, no. 20, pp. 2411–2417, 2000.
  23. B. Staels, J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf, and J.-C. Fruchart, “Mechanism of action of fibrates on lipid and lipoprotein metabolism,” Circulation, vol. 98, no. 19, pp. 2088–2093, 1998.
  24. A. Chait, R. L. Brazg, and D. L. Tribble, “Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B,” American Journal of Medicine, vol. 94, no. 4, pp. 350–356, 1993. View at PublisherView at Google Scholar
  25. B. M. Forman, J. Chen, and R. M. Evans, “Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 9, pp. 4312–4317, 1997. View at PublisherView at Google Scholar
  26. A. Ibabe, A. Herrero, and M. P. Cajaraville, “Modulation of peroxisome proliferator-activated receptors (PPARs) by PPARα- and PPARγ-specific ligands and by 17β-estradiol in isolated zebrafish hepatocytes,” Toxicology in Vitro, vol. 19, no. 6, pp. 725–735, 2005. View at PublisherView at Google ScholarView at PubMed
  27. “Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study,” The Lancet, vol. 357, no. 9260, pp. 905–910, 2001. View at PublisherView at Google Scholar
  28. A. Chawla, E. J. Schwarz, D. D. Dimaculangan, and M. A. Lazar, “Peroxisome proliferator-activated receptor (PPAR) γ: adipose-predominant expression and induction early in adipocyte differentiation,” Endocrinology, vol. 135, no. 2, pp. 798–800, 1994. View at PublisherView at Google Scholar
  29. N. Marx, U. Schönbeck, M. A. Lazar, P. Libby, and J. Plutzky, “Peroxisome proliferator-activated receptor γ activators inhibit gene expression and migration in human vascular smooth muscle cells,” Circulation Research, vol. 83, no. 11, pp. 1097–1103, 1998.
  30. D. S. H. Bell, “β-cell rejuvenation with thiazolidinediones,” American Journal of Medicine, vol. 115, no. 8, supplement 1, pp. 20–23, 2003. View at PublisherView at Google Scholar
  31. H. Yki-Jarvinen, “Thiazolidinediones,” The New England Journal of Medicine, vol. 351, no. 11, pp. 1106–1118, 2004. View at PublisherView at Google ScholarView at PubMed
  32. L. Al-Khalili, M. Forsgren, K. Kannisto, J. R. Zierath, F. Lönnqvist, and A. Krook, “Enhanced insulin-stimulated glycogen synthesis in response to insulin, metformin or rosiglitazone is associated with increased mRNA expression of GLUT4 and peroxisomal proliferator activator receptor γ co-activator 1,” Diabetologia, vol. 48, no. 6, pp. 1173–1179, 2005. View at PublisherView at Google ScholarView at PubMed
  33. T. W. Kurtz and M. Pravenec, “Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system,” Journal of Hypertension, vol. 22, no. 12, pp. 2253–2261, 2004. View at PublisherView at Google Scholar
  34. W. R. Oliver Jr., J. L. Shenk, and M. R. Snaith et al., “A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 9, pp. 5306–5311, 2001. View at PublisherView at Google ScholarView at PubMed
  35. G. D. Barish, V. A. Narkar, and R. M. Evans, “PPAR δ: a dagger in the heart of the metabolic syndrome,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 590–597, 2006. View at PublisherView at Google ScholarView at PubMed
  36. C.-H. Lee, A. Chawla, N. Urbiztondo, D. Liao, W. A. Boisvert, and R. M. Evans, “Transcriptional repression of atherogenic inflammation: modulation by PPARδ,” Science, vol. 302, no. 5644, pp. 453–457, 2003. View at PublisherView at Google Scholar
  37. Y. Shi, M. Hon, and R. M. Evans, “The peroxisome proliferator-activated receptor δ, an integrator of transcriptional repression and nuclear receptor signaling,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 5, pp. 2613–2618, 2002. View at PublisherView at Google ScholarView at PubMed
  38. T. Tanaka, J. Yamamoto, and S. Iwasaki et al., “Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 26, pp. 15924–15929, 2003. View at PublisherView at Google Scholar
  39. T. L. Graham, C. Mookherjee, K. E. Suckling, C. N. A. Palmer, and L. Patel, “The PPARδ agonist GW0742X reduces atherosclerosis in LDLR-/- mice,” Atherosclerosis, vol. 181, no. 1, pp. 29–37, 2005. View at PublisherView at Google ScholarView at PubMed
  40. R. C. Turner, H. Millns, and H. A. W. Neil et al., “Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23),” British Medical Journal, vol. 316, no. 7134, pp. 823–828, 1998.
  41. M. Guerin, W. Le Goff, T. S. Lassel, A. van Tol, G. Steiner, and M. J. Chapman, “Proatherogenic role of elevated CE transfer from HDL to VLDL1 and dense LDL ia type 2 diabetes impact of the degree of triglyceridemia,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 2, pp. 282–288, 2001.
  42. B. Verges, “Diabetic dyslipidaemia: insights for optimizing patient management,” Current Medical Research and Opinion, vol. 21, no. 1, pp. S29–S40, 2005. View at PublisherView at Google ScholarView at PubMed
  43. M.-R. Taskinen, “Diabetic dyslipidaemia: from basic research to clinical practice,” Diabetologia, vol. 46, no. 6, pp. 733–749, 2003. View at PublisherView at Google ScholarView at PubMed
  44. B. Vergges, “New insight into the pathophysiology of lipid abnormalities in type 2 diabetes,” Diabetes and Metabolism, vol. 31, no. 5, pp. 429–439, 2005. View at PublisherView at Google Scholar
  45. L. Duvillard, E. Florentin, and G. Lizard et al., “Cell surface expression of LDL receptor is decreased in type 2 diabetic patients and is normalized by insulin therapy,” Diabetes Care, vol. 26, no. 5, pp. 1540–1544, 2003. View at PublisherView at Google Scholar
  46. W. F. Graier and G. M. Kostner, “Glycated low-density lipoprotein and atherogenesis: the missing link between diabetes mellitus and hypercholesterolaemia?,” European Journal of Clinical Investigation, vol. 27, no. 6, pp. 457–459, 1997. View at PublisherView at Google Scholar
  47. S. A. Santini, G. Marra, and B. Giardina et al., “Defective plasma antioxidant defenses and enhanced susceptibility to lipid peroxidation in uncomplicated IDDM,” Diabetes, vol. 46, no. 11, pp. 1853–1858, 1997. View at PublisherView at Google Scholar
  48. M. I. Freed, R. Ratner, and S. M. Marcovina et al., “Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus,” American Journal of Cardiology, vol. 90, no. 9, pp. 947–952, 2002. View at PublisherView at Google Scholar
  49. M. Evans, R. A. Anderson, and J. Graham et al., “Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus,” Circulation, vol. 101, no. 15, pp. 1773–1779, 2000.
  50. G. Chinetti, S. Lestavel, and V. Bocher et al., “PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway,” Nature Medicine, vol. 7, no. 1, pp. 53–58, 2001. View at PublisherView at Google ScholarView at PubMed
  51. A. Chawla, W. A. Boisvert, and C.-H. Lee et al., “A PPAR γ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis,” Molecular Cell, vol. 7, no. 1, pp. 161–171, 2001. View at PublisherView at Google Scholar
  52. D. L. Sprecher, C. Massien, and G. Pearce et al., “Triglyceride: high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor δ agonist,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 2, pp. 359–365, 2007. View at PublisherView at Google ScholarView at PubMed
  53. I. M. Stratton, A. I. Adler, and H. A. W. Neil et al., “Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study,” British Medical Journal, vol. 321, no. 7258, pp. 405–412, 2000. View at PublisherView at Google Scholar
  54. “Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group,” The Lancet, vol. 352, no. 9131, pp. 854–865, 1998. View at PublisherView at Google Scholar
  55. A. D. Mooradian, J. Chehade, and J. E. Thurman, “The role of thiazolidinediones in the treatment of patients with type 2 diabetes mellitus,” Treatments in Endocrinology, vol. 1, no. 1, pp. 13–20, 2002. View at PublisherView at Google Scholar
  56. K. Cusi, K. Maezono, and A. Osman et al., “Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle,” Journal of Clinical Investigation, vol. 105, no. 3, pp. 311–320, 2000. View at PublisherView at Google Scholar
  57. Z. T. Bloomgarden, “Inflammation and insulin resistance,” Diabetes Care, vol. 26, no. 5, pp. 1619–1623, 2003. View at PublisherView at Google Scholar
  58. H. Duez, Y.-S. Chao, and M. Hernandez et al., “Reduction of atherosclerosis by the peroxisome proliferator-activated receptor α agonist fenofibrate in mice,” Journal of Biological Chemistry, vol. 277, no. 50, pp. 48051–48057, 2002. View at PublisherView at Google ScholarView at PubMed
  59. K. D. O'Brien, M. D. Allen, and T. O. McDonald et al., “Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques: implications for the mode of progression of advanced coronary atherosclerosis,” Journal of Clinical Investigation, vol. 92, no. 2, pp. 945–951, 1993.
  60. S. M. Jackson, F. Parhami, and X.-P. Xi et al., “Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 9, pp. 2094–2104, 1999.
  61. Y. Rival, N. Benéteau, and T. Taillandier et al., “PPARα and PPARδ activators inhibit cytokine-induced nuclear translocation of NF-κB and expression of VCAM-1 in EAhy926 endothelial cells,” European Journal of Pharmacology, vol. 435, no. 2-3, pp. 143–151, 2002. View at PublisherView at Google Scholar
  62. J. Turay, V. Grniakova, and J. Valka, “Changes in paraoxonase and apolipoprotein A-I, B, C-III and E in subjects with combined familiar hyperlipoproteinemia treated with ciprofibrate,” Drugs under Experimental and Clinical Research, vol. 26, no. 3, pp. 83–88, 2000.
  63. H. B. Liu, Y. S. Hu, R. L. Medcalf, R. W. Simpson, and A. E. Dear, “Thiazolidinediones inhibit TNFα induction of PAI-1 independent of PPARγ activation,” Biochemical and Biophysical Research Communications, vol. 334, no. 1, pp. 30–37, 2005. View at PublisherView at Google ScholarView at PubMed
  64. P. O. Szapary, L. T. Bloedon, and F. F. Samaha et al., “Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 1, pp. 182–188, 2006. View at PublisherView at Google ScholarView at PubMed
  65. N. Marui, M. K. Offermann, and R. Swerlick et al., “Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells,” Journal of Clinical Investigation, vol. 92, no. 4, pp. 1866–1874, 1993. View at PublisherView at Google Scholar
  66. Z. S. Galis, K. Asanuma, D. Godin, and X. Meng, “N-acetyl-cysteine decreases the matrix-degrading capacity of macrophage- derived foam cells: new target for antioxidant therapy?,” Circulation, vol. 97, no. 24, pp. 2445–2453, 1998.
  67. I. Inoue, S.-I. Goto, and T. Matsunaga et al., “The ligands/activators for peroxisome proliferator-activated receptor α (PPARα) and PPARγ increase Cu2+, Zn2+ -superoxide dismutase and decrease p22phox message expressions in primary endothelial cells,” Metabolism, vol. 50, no. 1, pp. 3–11, 2001. View at PublisherView at Google Scholar
  68. L. Tao, H.-R. Liu, and E. Gao et al., “Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-γ agonist in hypercholesterolemia,” Circulation, vol. 108, no. 22, pp. 2805–2811, 2003. View at PublisherView at Google Scholar
  69. R. Garg, Y. Kumbkarni, and A. Aljada et al., “Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation obese subjects,” Hypertension, vol. 36, no. 3, pp. 430–435, 2000.
  70. Y. Rival, N. Beneteau, and V. Chapuis et al., “Cardiovascular drugs inhibit MMP-9 activity from human THP-1 macrophages,” DNA and Cell Biology, vol. 23, no. 5, pp. 283–292, 2004. View at PublisherView at Google Scholar
  71. J. M. Forbes, L. T. L. Yee, and V. Thallas et al., “Advanced glycation end product-interventions reduce diabetes-accelerated atherosclerosis,” Diabetes, vol. 53, no. 7, pp. 1813–1823, 2004. View at PublisherView at Google Scholar
  72. H. Vlassara, “The AGE-receptor in the pathogenesis of diabetic complications,” Diabetes/Metabolism Research and Reviews, vol. 17, no. 6, pp. 436–443, 2001. View at PublisherView at Google ScholarView at PubMed
  73. M. Brownlee, “Biochemistry and molecular cell biology of diabetic complications,” Nature, vol. 414, no. 6865, pp. 813–820, 2001. View at PublisherView at Google ScholarView at PubMed
  74. T. Soulis-Liparota, M. Cooper, D. Papazoglou, B. Clarke, and G. Jerums, “Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat,” Diabetes, vol. 40, no. 10, pp. 1328–1334, 1991. View at PublisherView at Google Scholar
  75. R.-Y. Lin, R. P. Choudhury, and W. Cai et al., “Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice,” Atherosclerosis, vol. 168, no. 2, pp. 213–220, 2003. View at PublisherView at Google Scholar
  76. S. Rahbar, R. Natarajan, K. Yerneni, S. Scott, N. Gonzales, and J. L. Nadler, “Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation,” Clinica Chimica Acta, vol. 301, no. 1-2, pp. 65–77, 2000. View at PublisherView at Google Scholar
  77. R. Candido, T. J. Allen, and M. Lassila et al., “Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis,” Circulation, vol. 109, no. 12, pp. 1536–1542, 2004. View at PublisherView at Google Scholar
  78. R. Candido, K. A. Jandeleit-Dahm, and Z. Cao et al., “Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice,” Circulation, vol. 106, no. 2, pp. 246–253, 2002. View at PublisherView at Google Scholar
  79. P. Rossing, P. Hougaard, K. Borch-Johnsen, and H.-H. Parving, “Predictors of mortality in insulin dependent diabetes; 10 year observational follow up study,” British Medical Journal, vol. 313, no. 7060, pp. 779–784, 1996.
  80. I. Muhlhauser, P. T. Sawicki, M. Blank, H. Overmann, B. Richter, and M. Berger, “Reliability of causes of death in persons with type I diabetes,” Diabetologia, vol. 45, no. 11, pp. 1490–1497, 2002. View at PublisherView at Google ScholarView at PubMed
  81. J. M. Stephenson, S. Kenny, L. K. Stevens, J. H. Fuller, and E. Lee, “Proteinuria and mortality in diabetes: the WHO multinational study of vascular disease in diabetes,” Diabetic Medicine, vol. 12, no. 2, pp. 149–155, 1995.
  82. A. C. Calkin, S. Giunti, K. A. Jandeleit-Dahm, T. J. Allen, M. E. Cooper, and M. C. Thomas, “PPAR-α and -γ agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse,” Nephrology Dialysis Transplantation, vol. 21, no. 9, pp. 2399–2405, 2006. View at PublisherView at Google ScholarView at PubMed
  83. R. E. Buckingham, K. A. Al-Barazanji, and C. D. N. Toseland et al., “Peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in zucker fatty rats,” Diabetes, vol. 47, no. 8, pp. 1326–1334, 1998. View at PublisherView at Google Scholar
  84. K. Isshiki, M. Haneda, D. Koya, S. Maeda, T. Sugimoto, and R. Kikkawa, “Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats,” Diabetes, vol. 49, no. 6, pp. 1022–1032, 2000. View at PublisherView at Google Scholar
  85. M. Fujii, R. Takemura, and M. Yamaguchi et al., “Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats,” Metabolism, vol. 46, no. 9, pp. 981–983, 1997. View at PublisherView at Google Scholar
  86. Y. Hattori, S. Hattori, and K. Kasai, “Troglitazone upregulates nitric oxide synthesis in vascular smooth muscle cells,” Hypertension, vol. 33, no. 4, pp. 943–948, 1999.
  87. A. Keech, R. J. Simes, and P. Barter et al., “Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial,” The Lancet, vol. 366, no. 9500, pp. 1849–1861, 2005. View at PublisherView at Google Scholar
  88. J.-C. Ansquer, C. Foucher, S. Rattier, M.-R. Taskinen, and G. Steiner, “Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS),” American Journal of Kidney Diseases, vol. 45, no. 3, pp. 485–493, 2005. View at PublisherView at Google ScholarView at PubMed
  89. E. Imano, T. Kanda, and Y. Nakatani et al., “Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy,” Diabetes Care, vol. 21, no. 12, pp. 2135–2139, 1998. View at PublisherView at Google Scholar
  90. T. Nakamura, C. Ushiyama, and S. Suzuki et al., “Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in type 2 diabetic patients with microalbuminuria or macroalbuminuria,” Diabetic Medicine, vol. 18, no. 4, pp. 308–313, 2001. View at PublisherView at Google Scholar
  91. T. Nakamura, C. Ushiyama, N. Shimada, K. Hayashi, I. Ebihara, and H. Koide, “Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients,” Journal of Diabetes and Its Complications, vol. 14, no. 5, pp. 250–254, 2000. View at PublisherView at Google Scholar
  92. H. B. Rubins, S. J. Robins, and D. Collins et al., “Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT),” Archives of Internal Medicine, vol. 162, no. 22, pp. 2597–2604, 2002. View at PublisherView at Google Scholar
  93. P. Koskinen, M. Manttari, V. Manninen, J. K. Huttunen, O. P. Heinonen, and M. H. Frick, “Coronary heart disease incidence in NIDDM patients in the Helsinki heart study,” Diabetes Care, vol. 15, no. 7, pp. 820–825, 1992. View at PublisherView at Google Scholar
  94. F. Pistrosch, J. Passauer, S. Fischer, K. Fuecker, M. Hanefeld, and P. Gross, “In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control,” Diabetes Care, vol. 27, no. 2, pp. 484–490, 2004. View at PublisherView at Google Scholar
  95. S. M. Haffner, A. S. Greenberg, W. M. Weston, H. Chen, K. Williams, and M. I. Freed, “Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus,” Circulation, vol. 106, no. 6, pp. 679–684, 2002. View at PublisherView at Google Scholar
  96. N. Varo, D. Vicent, and P. Libby et al., “Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones,” Circulation, vol. 107, no. 21, pp. 2664–2669, 2003. View at PublisherView at Google Scholar
  97. N. Marx, A. Imhof, and J. Froehlich et al., “Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease,” Circulation, vol. 107, no. 15, pp. 1954–1957, 2003. View at PublisherView at Google ScholarView at PubMed
  98. J. A. Dormandy, B. Charbonnel, and D. J. Eckland et al., “Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial,” The Lancet, vol. 366, no. 9493, pp. 1279–1289, 2005. View at PublisherView at Google ScholarView at PubMed
  99. S. E. Kahn, S. M. Haffner, and M. A. Heise et al., “Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy,” The New England Journal of Medicine, vol. 355, no. 23, pp. 2427–2443, 2006. View at PublisherView at Google ScholarView at PubMed
  100. H. C. Gerstein, S. Yusuf, and J. Bosch et al., “Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial,” The Lancet, vol. 368, no. 9541, pp. 1096–1105, 2006. View at PublisherView at Google Scholar
  101. S. E. Nissen and K. Wolski, “Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes,” The New England Journal of Medicine, vol. 356, no. 24, pp. 2457–2471, 2007. View at PublisherView at Google Scholar
  102. R. Chakrabarti, R. K. Vikramadithyan, and P. Misra et al., “Ragaglitazar: a novel PPAR α & PPAR γ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models,” British Journal of Pharmacology, vol. 140, no. 3, pp. 527–537, 2003. View at PublisherView at Google ScholarView at PubMed
  103. S. Mittra, G. Sangle, and R. Tandon et al., “Increase in weight induced by muraglitazar, a dual PPARα/γ agonist, in db/db mice: adipogenesis/or oedema?,” British Journal of Pharmacology, vol. 150, no. 4, pp. 480–487, 2007. View at PublisherView at Google ScholarView at PubMed
  104. A. C. Calkin, T. J. Allen, and M. Lassila et al., “Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse,” Atherosclerosis, vol. 195, no. 1, pp. 17–22, 2007. View at PublisherView at Google ScholarView at PubMed
  105. T. Claudel, M. D. Leibowitz, and C. Fievet et al., “Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 5, pp. 2610–2615, 2001. View at PublisherView at Google ScholarView at PubMed
  106. S. H. Zuckerman, R. F. Kauffman, and G. F. Evans, “Peroxisome proliferator-activated receptor α,γ coagonist LY465608 inhibits macrophage activation and atherosclerosis in apolipoprotein E knockout mice,” Lipids, vol. 37, no. 5, pp. 487–494, 2002. View at PublisherView at Google Scholar
  107. A. S. M. Zadelaar, L. S. M. Boesten, and J. W. Jukema et al., “Dual PPARα/γ agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE3Leiden mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 11, pp. 2560–2566, 2006. View at PublisherView at Google ScholarView at PubMed
  108. E. C. Chira, T. S. McMillen, and S. Wang et al., “Tesaglitazar, a dual peroxisome proliferator-activated receptor α/γ agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice,” Atherosclerosis, vol. 195, no. 1, pp. 100–109, 2007. View at PublisherView at Google ScholarView at PubMed
  109. J. B. Buse, C. J. Rubin, and R. Frederich et al., “Muraglitazar, a dual (α/γ) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes,” Clinical Therapeutics, vol. 27, no. 8, pp. 1181–1195, 2005. View at PublisherView at Google ScholarView at PubMed
  110. B. K. Skrumsager, K. K. Nielsen, M. Müller, G. Pabst, P. G. Drake, and B. Edsberg, “Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR α and γ agonist in healthy subjects and patients with type 2 diabetes,” Journal of Clinical Pharmacology, vol. 43, no. 11, pp. 1244–1256, 2003. View at PublisherView at Google ScholarView at PubMed
  111. D. M. Kendall, C. J. Rubin, and P. Mohideen et al., “Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (α/γ) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a double-blind, randomized, pioglitazone-comparative study,” Diabetes Care, vol. 29, no. 5, pp. 1016–1023, 2006. View at PublisherView at Google ScholarView at PubMed
  112. M. F. Saad, S. Greco, and K. Osei et al., “Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm,” Diabetes Care, vol. 27, no. 6, pp. 1324–1329, 2004. View at PublisherView at Google Scholar
  113. B. Fagerberg, S. Edwards, and T. Halmos et al., “Tesaglitazar, a novel dual peroxisome proliferator-activated receptor α/γ agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population,” Diabetologia, vol. 48, no. 9, pp. 1716–1725, 2005. View at PublisherView at Google ScholarView at PubMed
  114. B. J. Goldstein, J. Rosenstock, D. Anzalone, C. Tou, and K. P. Öhman, “Effect of tesaglitazar, a dual PPAR α/γ agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial,” Current Medical Research and Opinion, vol. 22, no. 12, pp. 2575–2590, 2006. View at PublisherView at Google ScholarView at PubMed
  115. B. B. Lohray, V. B. Lohray, and A. C. Bajji et al., “(-)3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity,” Journal of Medicinal Chemistry, vol. 44, no. 16, pp. 2675–2678, 2001. View at PublisherView at Google Scholar
  116. S. E. Nissen, K. Wolski, and E. J. Topol, “Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus,” Journal of the American Medical Association, vol. 294, no. 20, pp. 2581–2586, 2005. View at PublisherView at Google ScholarView at PubMed
  117. AstraZeneca International, “Press release 4 May 2006—AstraZeneca discontinues development of GALIDA TM (tesaglitazar),” 2007, http://www.astrazeneca.com/pressrelease/5240.aspx.
  118. M. A. Dominick, M. R. White, and T. P. Sanderson et al., “Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR α/γ agonist: evidence for urolithiasis as the inciting event in the mode of action,” Toxicologic Pathology, vol. 34, no. 7, pp. 903–920, 2006. View at PublisherView at Google ScholarView at PubMed
  119. T. R. van Vleet, M. R. White, and T. P. Sanderson et al., “Subchronic urinary bladder effects of muraglitazar in male rats,” Toxicological Sciences, vol. 96, no. 1, pp. 58–71, 2007. View at PublisherView at Google ScholarView at PubMed
  120. H. Hellmold, H. Zhang, and U. Andersson et al., “Tesaglitazar, a PPARα/γ agonist, induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats,” Toxicological Sciences, vol. 98, no. 1, pp. 63–74, 2007. View at PublisherView at Google ScholarView at PubMed
  121. R. Artis, “A novel PPAR pan-modulator improves lipid and glucose homeostasis in insulin resistant and diabetic molise models,” Diabetes, no. 55, supplement 2, p. A480, 2006.
  122. H. K. Ortmeyer, “A novel PPAR pan-modulator improve lipid and glucose homeostasis in insulin resistant and diabetic mouse models,” Diabetes, no. 52, supplement 2, p. A159, 2004.
  123. Y. Wang, Y. Wang, and Q. Yang et al., “Effects of bezafibrate on the expression of endothelial nitric oxide synthase gene and its mechanisms in cultured bovine endothelial cells,” Atherosclerosis, vol. 187, no. 2, pp. 265–273, 2006. View at PublisherView at Google ScholarView at PubMed
  124. H. Toba, S. Miki, and T. Shimizu et al., “The direct antioxidative and anti-inflammatory effects of peroxisome proliferator-activated receptors ligands are associated with the inhibition of angiotensin converting enzyme expression in streptozotocin-induced diabetic rat aorta,” European Journal of Pharmacology, vol. 549, no. 1–3, pp. 124–132, 2006. View at PublisherView at Google ScholarView at PubMed
  125. F. Chang, L. A. Jaber, H. D. Berlie, and M. B. O'Connell, “Evolution of peroxisome proliferator-activated receptor agonists,” Annals of Pharmacotherapy, vol. 41, no. 6, pp. 973–983, 2007. View at PublisherView at Google ScholarView at PubMed
  126. A. Tenenbaum, M. Motro, and E. Z. Fisman, “Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons,” Cardiovascular Diabetology, vol. 4, p. 14, 2005. View at PublisherView at Google ScholarView at PubMed
  127. R. S. Elkeles, J. R. Diamond, and C. Poulter et al., “Cardiovascular outcomes in type 2 diabetes: a double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park diabetes cardiovascular disease prevention (SENDCAP) study,” Diabetes Care, vol. 21, no. 4, pp. 641–648, 1998. View at PublisherView at Google Scholar
  128. L. Arcavi, S. Behar, and A. Caspi et al., “High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study,” American Heart Journal, vol. 147, no. 2, pp. 239–245, 2004. View at PublisherView at Google ScholarView at PubMed